New report on the impacts of Michigan’s Medicaid expansion shows positive effects and opportunities for improvement

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it

The FDA seems open to a new end­point that could ac­cel­er­ate the de­vel­op­ment of new treat­ments for mul­ti­ple myelo­ma. The agency’s On­co­log­ic Drugs Ad­vi­so­ry Com­mit­tee

Asceneuron’s lead compound, ASN51, is intended for Alzheimer’s disease treatment. Credit: fizkes/Shutterstock. Clinical-stage biotech company Asceneuron has announced an oversubscribed Series C financing round, securing